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The molecular pathology of infant medulloblastoma (iMB) has not been systematically characterised, 
particularly in relation to the consensus molecular subgroups or outcomes, to inform contemporary 
treatments, risk-stratification and clinical trials.  We assembled 208 iMBs (0-5yrs) with full central 
clinical and pathological review, subgroup assignation, and comprehensive profiling of copy-number 
and mutational features. iMB represented a three-subgroup disease with MBSHH and MBGrp3 
predominant (41% each; MBGrp4, 17%). MBSHH significantly associated with DN/MBEN pathology (72% 
(50/69); p=6.8x10-19), but also contained classic (CLA; n=15) and LCA (n=4) tumours (28%; 19/69) 
throughout the age-range. Multivariate survival analysis identified sub-total resection (STR; HR 6.3, 
p=3.1x10-5) and DN/MBEN (HR 0.1, p=0.004) as independent prognostic factors, however metastatic 
(M+) disease and other established biological features were not associated with outcome. A novel 
MBSHH survival model defined CLA/LCA and/or STR tumours as very high-risk (44% (27/61); 10yr OS, 
24%), with 18.8-fold relative-risk compared to favourable-risk totally-resected DN/MBEN disease 
(56% (34/61); 10yr OS, 93%). MBGrp3 was strongly associated with LCA (23%, 14/62) and MYC 
amplification (19%, 12/62). Presence of either feature defined a very high-risk group (27% (18/62); 
10yr OS, 23%), with common rapid progression on current therapies and an 11.7-fold relative-risk 
than remaining MBGrp3 tumours (73% (45/62; 10yr OS, 74%; standard-risk). Only MBSHH DN/MBEN 
tumours showed potential of rescue at relapse following initial therapy (56% survival post-relapse); 
other relapses were almost universally fatal. Combined diagnostic assessment of iMB subgroup, 
pathology and molecular biomarkers will be essential to direct improved risk-stratified therapies, 
and novel approaches for very high-risk patients. 
 
